MDGL
HEALTHCAREMadrigal Pharmaceuticals Inc
$539.73+37.26 (+7.42%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MDGL Today?
No stock-specific AI insight has been generated for MDGL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$265.00$615.00
$539.73
Fundamentals
Market Cap$12.4B
P/E Ratio—
EPS$-12.86
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume569K
Avg Volume (10D)—
Shares Outstanding23.1M
MDGL News
22 articles- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 7, 2026
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpYahoo Finance·May 7, 2026
- Madrigal Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Madrigal (MDGL) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline ExpansionAdvfn·May 6, 2026
- Madrigal (MDGL) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate UpdatesYahoo Finance·May 6, 2026
- Avalo shares spike on skin drug data; BioNTech to cut staffBiopharmadive·May 6, 2026
- Arrowhead and Madrigal sign global licence for MASH RNAi therapyPharmaceutical-technology·May 6, 2026
- Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors?Yahoo Finance·May 6, 2026
- Madrigal outlays $1bn for Arrowhead’s siRNA MASH assetPharmaceutical-technology·May 5, 2026
- Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal PharmaceuticalsYahoo Finance·May 5, 2026
- Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH PipelineYahoo Finance·May 5, 2026
- 3 Biotech Stocks to Watch for Respectable Growth Beyond AI247 Wall St·May 3, 2026
- Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out forYahoo Finance·Apr 30, 2026
- Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 29, 2026
- Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026GlobeNewswire Inc.·Apr 22, 2026
- 3 Under-the-Radar Healthcare Stocks Worth Adding to Your WatchlistMotley Fool·Apr 16, 2026
- Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Its 20% Monthly Surge?Yahoo Finance·Apr 11, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
- Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowThe Motley Fool·Mar 25, 2026
All 22 articles loaded
Price Data
Open$518.11
Previous Close$502.47
Day High$520.78
Day Low$504.01
52 Week High$615.00
52 Week Low$265.00
52-Week Range
$265.00$615.00
$539.73
Fundamentals
Market Cap$12.4B
P/E Ratio—
EPS$-12.86
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume569K
Avg Volume (10D)—
Shares Outstanding23.1M
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—